...
首页> 外文期刊>Allergy & Rhinology >A postal survey of hereditary hemorrhagic telangectasia in the northeast of England
【24h】

A postal survey of hereditary hemorrhagic telangectasia in the northeast of England

机译:英格兰东北部的遗传性出血性毛细血管扩张的邮政调查

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The aim of this study is to identify the demographics and epistaxis burden of hereditary hemorrhagic telangiectasia (HHT). A questionnaire was sent to participants with HHT who were recruited from a prospectively maintained respiratory clinic data base in a tertiary hospital. Details on demographics, HHT symptoms, family history, epistaxis severity, and treatment received were recorded. There were 34 of 60 responses (57%). Two responses were from families of the deceased. Of the 32 evaluable patients (men, 14; women 18), the average age was 51 years (range, 23‐78 years). The average age of HHT diagnosis was 31 years (range, 3‐61 years). The diagnosis of HHT was made by the respiratory team in 13 patients; neurologist (2); ear, nose, and throat (ENT) specialist (4); general practitioner (5); hematologist (4); gastroenterologist (1); and not mentioned in two patients. Twenty-seven of 32 patients (84%) had a positive family history of HHT. Only 13 patients had formal genetic testing (4 endoglin, 1 activin receptor‐like kinase, 8 unknown gene). All patients who presented to the respiratory clinic had a background of epistaxis, which was noted on presentation. The average age at initial epistaxis was 14 years (range, 2‐50 years). The frequency of epistaxis was daily 63% (n = 20), weekly 9% (3), monthly 16% (5), and a few times a year 10% (3), and unstated in one patient. Nine of 32 patients (28%) required a transfusion. Six patients thought that they were unable to perform daily activities due to epistaxis. Only 15 of 32 patients (47%) were under the care of an ENT specialist. The treatment plan for epistaxis management was deemed good by 7 patients, adequate in 8, poor in 6, and not stated by 11 patients. In conclusion, this survey is the first to quantify the epistaxis burden within the northeast of England. The management of epistaxis needs specific education and treatment to optimize the quality of life among these patients.
机译:这项研究的目的是确定遗传性出血性毛细血管扩张(HHT)的人口统计学和鼻epi负担。向HHT参与者发送了问卷,这些参与者是从一家三级医院的前瞻性维护的呼吸诊所数据库中招募的。记录有关人口统计学,HHT症状,家族史,鼻epi严重程度和所接受治疗的详细信息。 60回应中有34(57%)。死者家属有两个回应。在32例可评估的患者中(男性14例;女性18例),平均年龄为51岁(范围23-78岁)。 HHT诊断的平均年龄为31岁(范围3-61岁)。呼吸小组对HHT的诊断为13例患者。神经科医生(2);耳鼻喉专科医师(4);全科医生(5);血液科医生(4);肠胃科医生(1);并没有在两名患者中提及。 32例患者中有27例(84%)的HHT家族史为阳性。只有13例患者接受了正式的基因检测(4个内皮糖蛋白,1个激活素受体样激酶,8个未知基因)。所有到呼吸科门诊就诊的患者都有鼻epi的背景,在就诊时注意到。初次epi鼻的平均年龄为14岁(范围2-50岁)。鼻epi的发生频率为每天63%(n = 20),每周9%(3),每月16%(5)和每年几次10%(3),其中一位患者未发现。 32名患者中有9名(28%)需要输血。六名患者认为由于鼻出血他们无法进行日常活动。在32名患者中,只有15名(47%)在耳鼻喉专科医生的照料下。鼻epi治疗的治疗计划被7例认为是好的,8例是适当的,6例是差的,11例患者没有陈述。总而言之,这项调查是第一个量化英格兰东北地区的鼻epi负担的调查。鼻epi的治疗需要特殊的教育和治疗,以优化这些患者的生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号